Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer

OBJECTIVE: This article investigated whether Runt-Related Transcription Factor 3 (RUNX3) and enhancer of zeste homolog 2 (EZH2) can be used to evaluate the clinical efficacy of neoadjuvant therapy and prognosis of locally advanced rectal cancer (LARC). METHODS: Eighty LARC patients admitted to the T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Likun, Wu, Xueliang, Xu, Wengui, Gao, Lei, Wang, Ximo, Li, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907660/
https://www.ncbi.nlm.nih.gov/pubmed/35280723
http://dx.doi.org/10.3389/fonc.2022.713335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907660/
https://www.ncbi.nlm.nih.gov/pubmed/35280723
http://dx.doi.org/10.3389/fonc.2022.713335

Ejemplares similares